Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

onths

Ending December 31, 2008

Low High

GAAP to adjusted net income calculation

GAAP net income $214.8 $227.2

Adjusted for:

Licensing charges 8.5 8.5

Global supply chain initiative 30.0 30.0

Loss on early extinguishment of debt 1.1 1.1

Gain on sale of securities (9.6) (9.6)

Legal settlement (15.0) (15.0)

Income taxes (14.7) (15.2)

Adjusted net income 215.1 227.0

Add: Interest expense on CODES, net of tax 8.2 8.2

Adjusted net income, adjusted

for interest on CODES $223.3 $235.2

Diluted earnings per share

Diluted earnings per share - GAAP $1.90 $2.00

Diluted earnings per share - Adjusted $1.90 $2.00

Diluted weighted average common

shares outstanding 117.6 117.6

The reconciliation table is based in part on management's estimate of net income for the year ending December 31, 2008. Watson expects certain known GAAP charges for 2008, as presented in the schedule above. Other GAAP charges that may be excluded from adjusted net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges, such as potential asset impairment charges, are dependent upon future events and valuations that have not yet been performed.

The following table presents a
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , May 21, 2015  Prima Biomed ... company that is striving to become a leader in ... cancer, recently announced that the final CVac data from ... shown a clear trend for a clinically meaningful improvement ... in second remission patients. In the group ...
(Date:5/21/2015)... 21, 2015 W. R. Grace ... facility in Worms, Germany has received good manufacturing ... of the International Pharmaceutical Excipient Council (IPEC) Foundation. ... produce its SYLOID® FP brand of pharmaceutical grade ... following the Curtis Bay, Maryland (USA) and Sorocaba, ...
(Date:5/21/2015)... , May 20, 2015 Research and Markets ... addition of the "2015 Global Survey on ... offering. The primary goal of this ... cytometry instruments and reagents. Key information the survey ... selection of flow cytometers, predominantly used applications for ...
(Date:5/20/2015)... FRANCISCO, Calif. , May 20, 2015 /PRNewswire/ ... ) today presented preliminary data demonstrating the ability ... idiopathic pulmonary fibrosis (IPF) from other interstitial lung ... findings suggest the classifier,s potential to help thousands ... to resolve ambiguity in IPF diagnosis – a ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
... Oral Presentation of the US Oncology Adjuvant Trial ... Symposium Showed Taxotere(R) and Cyclophosphamide ... SAN ANTONIO, Dec. 13 Results presented ... (SABCS) showed that for,women with early stage breast ...
... Follicular Lymphoma, and Chronic Lymphocytic Leukemia -- Collaboration to develop microRNA-based diagnostics test, early ... detection and prognosis., -- 43,000 people will be diagnosed ... ... specific ...
... ClinicalAnalytics 4.0 Links Images of Study Participant Eyes with ... to ... /PRNewswire/ - TrialStat Corporation, the industry,s,first clinical data solutions ... news that Notal Vision(TM), an,Israeli-based medical device company specializing ...
Cached Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 2Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 3Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 4Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma 5Notal Vision chooses TrialStat's ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial 2Notal Vision chooses TrialStat's ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial 3
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... for life in a place not known for extremes. ... the surface of Lake Huron, the third largest of ... water dissolving parts of an ancient underlying seabedharbor bizarre ... lake are rarely to be seen. Instead, brilliant purple ...
... This release is available in French . ... as one of the world leading pioneers in green chemistry, ... use of toxic, petrochemical-based solvents in favour of basic substances ... environmental benefits of the green approach are obvious and significant, ...
... Science, Technology and Innovation Policy, says there is ... environmental footprint. His research will provide input into ... initiative on IT and sustainability at the United ... this year. "It was once assumed that ...
Cached Biology News:Great Lake's sinkholes host exotic ecosystems 2Peptides-on-demand: McGill researcher's radical new green chemistry makes the impossible possible 2Green IT not helping climate change 2
... system with colony-picking capabilities, 110-120 V, uses ... proteins, oligonucleotides, carbohydrates, lipids, and other biomolecules ... applications. This system can also be used ... micrometers in diameter and for inoculating 96- ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
The Freeze 'N Squeeze DNA gel extraction kit uses a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. The kit includes materials for 100 preps....
Biology Products: